RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc.
Your view on RGRX
Overview
What the company does, where it operates, and who runs it.
About RegeneRx Biopharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- J. J. Finkelstein
- Headquarters
- 15245 Shady Grove Road, Rockville, MD, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- J. J. Finkelstein
- Headquarters
- 15245 Shady Grove Road, Rockville, MD, US
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration.
The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.
It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for RegeneRx Biopharmaceuticals, Inc., and the rating behind it. RGRX last traded at $0.0003; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for RegeneRx Biopharmaceuticals, Inc.. Starting points for RegeneRx Biopharmaceuticals, Inc.: EPS -$0.01, beta 4.73 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for RegeneRx Biopharmaceuticals, Inc.. RegeneRx Biopharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for RegeneRx Biopharmaceuticals, Inc.. Trailing twelve-month EPS for RegeneRx Biopharmaceuticals, Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for RegeneRx Biopharmaceuticals, Inc.. RegeneRx Biopharmaceuticals, Inc. has reported as a listed company since 2003. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
RegeneRx Biopharmaceuticals, Inc. valued side by side against its closest peers. RegeneRx Biopharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold RegeneRx Biopharmaceuticals, Inc., and how their positions are changing. At a $449 market value, institutional positions materially move RegeneRx Biopharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by RegeneRx Biopharmaceuticals, Inc. executives and directors. Shares of RegeneRx Biopharmaceuticals, Inc. have traded between $0.0002 and $0.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming RegeneRx Biopharmaceuticals, Inc.. RegeneRx Biopharmaceuticals, Inc. is a $449 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming RegeneRx Biopharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for RegeneRx Biopharmaceuticals, Inc.. Coverage tracks RegeneRx Biopharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.